The SURMOUNT-OSA Trial: Tirzepatide's Sleep Apnea Evidence
TRIAL-000009
Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.
What It Is
SURMOUNT-OSA is the clinical trial that established Zepbound's FDA approval for treating obstructive sleep apnea, distinct from its weight-management approval. It was actually two parallel 52-week studies, Study 1 enrolled participants unable or unwilling to use positive airway pressure (PAP) therapy, while Study 2 enrolled participants already using PAP therapy who planned to continue it during the trial.
Key Results
The trial measured improvement in the apnea-hypopnea index, the standard measure of OSA severity, using overnight sleep studies. Participants received tirzepatide gradually titrated up to their maximum tolerated dose (10 or 15 mg) alongside lifestyle intervention, or placebo. The trial demonstrated meaningful improvement in sleep apnea severity, forming the direct evidence base for Zepbound's distinct OSA indication.
A Genuinely Novel Trial Design
SURMOUNT-OSA specifically investigated whether tirzepatide could improve OSA by targeting its underlying cause, excess weight and tissue around the airway, rather than only managing symptoms the way PAP therapy does. The trial also used digital wearables and home sleep testing to capture more detailed data on how quickly improvement occurred and how it affected daily physical activity.
Why Two Separate Studies Mattered
Testing both people not currently using PAP therapy and people already using it separately let researchers understand tirzepatide's effect both as a standalone treatment and as a genuine complement to existing PAP therapy, rather than assuming it would work the same way in both situations.
References
- PMC: Tirzepatide for the Treatment of Obstructive Sleep Apnea, SURMOUNT-OSA Trial Design
- PMC: Effect of Tirzepatide on Patient-Reported Outcomes Among SURMOUNT-OSA Participants
Related Resources
Related Articles
Two Real, Distinct Study Designs
| Study | Population | Real Purpose |
|---|---|---|
| SURMOUNT-OSA Study 1 | Not using PAP therapy | Tirzepatide as standalone treatment |
| SURMOUNT-OSA Study 2 | Continuing PAP therapy | Tirzepatide as a complement to PAP |
See DietApp's main SURMOUNT Trials page for tirzepatide's broader weight-management evidence. Retatrutide has shown a similar real OSA benefit in its own nested substudy, see DietApp's TRIUMPH Trials page.
Frequently Asked Questions
Does this mean tirzepatide can replace CPAP? Not necessarily, Study 2 specifically tested it as a complement to continued PAP use, not a full replacement for everyone.
Is this OSA benefit unique to tirzepatide? No, weight loss itself is a real, established way to reduce OSA severity; retatrutide has shown a similar effect in its own trial data.
Do I need a sleep apnea diagnosis to be prescribed Zepbound for this? Yes, this is a distinct, separate FDA indication from Zepbound's weight-management approval, requiring its own diagnosis and prescribing basis.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Download DietApp.com to track your own progress alongside the evidence behind your treatment.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Last medically reviewed and updated: July 11, 2026.
surmount-osa-trial-tirzepatide